Cite
Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression
MLA
Gambacorta, Valentina, et al. “Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression.” Blood, vol. 134, no. Supplement 1, Nov. 2019, p. 514. EBSCOhost, https://doi.org/10.1182/blood-2019-127395.
APA
Gambacorta, V., Gnani, D., Zito, L., Beretta, S., Zanotti, L., Giacomo, O., Cittaro, D., Merelli, I., Ciceri, F., Di Micco, R., & Vago, L. (2019). Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression. Blood, 134(Supplement 1), 514. https://doi.org/10.1182/blood-2019-127395
Chicago
Gambacorta, Valentina, Daniela Gnani, Laura Zito, Stefano Beretta, Lucia Zanotti, Oliveira Giacomo, Davide Cittaro, et al. 2019. “Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression.” Blood 134 (Supplement 1): 514. doi:10.1182/blood-2019-127395.